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Abstract
Background: Management of lupus nephritis (LN) would be greatly aided by the discovery of biomarkers that
accurately reflect changes in disease activity. Here, we used a proteomics approach to identify potential urinary
biomarkers associated with LN.
Methods: Urine was obtained from 60 LN patients with paired renal biopsies, 25 active non-LN SLE patients, and
24 healthy controls. Using Luminex, 128 analytes were quantified and normalized to urinary creatinine levels. Data
were analyzed by linear modeling and non-parametric statistics, with corrections for multiple comparisons. A second
cohort of 33 active LN, 16 active non-LN, and 30 remission LN SLE patients was used to validate the results.
Results: Forty-four analytes were identified that were significantly increased in active LN as compared to active non-LN.
This included a number of unique proteins (e.g., TIMP-1, PAI-1, PF4, vWF, and IL-15) as well as known candidate LN
biomarkers (e.g., adiponectin, sVCAM-1, and IL-6), that differed markedly (>4-fold) between active LN and non-LN,
all of which were confirmed in the validation cohort and normalized in remission LN patients. These proteins
demonstrated an enhanced ability to discriminate between active LN and non-LN patients over several previously
reported biomarkers. Ten proteins were found to significantly correlate with the activity score on renal biopsy, eight
of which strongly discriminated between active proliferative and non-proliferative/chronic renal lesions.
Conclusions: A number of promising urinary biomarkers that correlate with the presence of active renal disease
and/or renal biopsy changes were identified and appear to outperform many of the existing proposed biomarkers.
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Background
Nephritis and its treatment constitute one of the major
causes of morbidity and mortality in systemic lupus
erythematosus (SLE). Approximately 50–60 % of SLE
patients will develop lupus nephritis (LN), with 30 % of
these patients developing significant renal impairment,
culminating in end-stage renal disease in 15 % of
patients [1, 2]. The clinical course of LN is highly variable,
being marked by unpredictable flares and variable
responses to treatment [3, 4]. As treatment of LN results
in significant immediate (e.g., infection) and delayed
(e.g., avascular necrosis and cardiovascular disease)
onset morbidity, the clinical care of LN patients seeks
to establish a balance between optimal control of
inflammation and tissue injury, while limiting exposure to
the side effects of immunosuppressive therapies [4]. One
of the challenges to this approach is the lack of bioche-
mical and serologic tests that accurately reflect the extent
and type of renal inflammation.
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Currently, monitoring of LN relies on serological
biomarkers and measures of renal dysfunction (e.g., pro-
teinuria and serum creatinine) [5]. Although elevated
anti-dsDNA antibody levels and hypocomplementemia
associate with disease activity in cross-sectional analyses,
longitudinal studies indicate that these traditional bio-
markers do not distinguish between active SLE patients
with and without LN, and are inconsistent at predicting
impending flares [3]. Proteinuria and other measures of
renal function also falter as accurate markers of immune-
mediated renal injury. As these measures reflect kidney
damage, reliance on proteinuria as a marker of renal
inflammation leads to delayed initiation of treatment.
Conversely, it may also lead to unnecessary prolongation
or premature tapering of immunosuppressive therapy due
to the persistence/resolution of urinary and/or functional
abnormalities that may not reflect resolution of the inci-
ting immunologic insult. Indeed LN-associated protei-
nuria frequently persists for years after renal injury,
normalizing in less than 50 % of patients within 2 years
[6], and often a renal biopsy is the only way to distinguish
between persistent activity and a chronic inactive lesion.
As a result, there has been tremendous interest in the
identification of biomarkers that accurately indicate the
extent, type, and course of renal inflammation in LN.
Of the potential compartments that can be surveyed
to identify LN-specific biomarkers, the urinary compart-
ment may hold the most promise. Several previous
studies have compared and contrasted levels of various
cyto/chemokines within serum and urine samples of
patients with active LN. These studies indicate that urine
levels most accurately reflect renal status as compared
with serum levels of these markers [7–13]. While these
studies have identified some potential urinary biomarkers
for diagnosis and management of LN, such as MCP-1
[7, 9, 14–16], NGAL [8, 12, 17–21], TWEAK [11, 14,
22–24], and sVCAM-1 [13, 25–27], there has been no
comprehensive survey of urinary proteins to evaluate
whether the above proteins constitute the best potential
markers of active renal disease. Furthermore, analyses are
limited on the association between urinary analyte levels
and renal disease activity indices since, in the majority of
studies, paired renal biopsies were not performed. In the
current study, a Luminex-based proteomics approach was
used to contrast levels of 128 urinary proteins found in
the urine of SLE patients with active LN (ALN) and active
SLE patients without LN (ANLN) to identify potential
novel urinary biomarkers.
Methods
Subjects and data collection
Two independent cohorts were used for this study. The
discovery cohort consisted of 85 active SLE patients
satisfying four ormore of the revised 1997 ACR classification
criteria for SLE [28] and 24 age- and sex-matched healthy
controls (HC). Patients were recruited from the University
Health Network and Mount Sinai Hospitals. Sixty patients
had ALN, confirmed by renal biopsy performed within
2 weeks of urine sampling for 88 % of patients (mean 7.5 days
from sample accrual), with the remainder having active
disease (score >0 on the clinical SLE Disease Activity Index-
2000 (SLEDAI-2 K) components [29]) and no clinical
evidence of LN. The validation cohort consisted of 33
patients with ALN (with ≥1 of the renal SLEDAI-2 K indices
scoring positive and requiring changes in therapy), 16
patients with ANLN, and 30 patients with a prior history of
biopsy-proven LN who were in remission with no urinary
abnormalities (except one patient with fixed proteinuria
(0.82 g/day) not requiring treatment).
Measurement of urinary analyte concentrations
All urine samples were spun to remove cellular debris
and frozen at –80 ° C. To avoid repeated freeze/thaws,
samples were thawed once on ice, sub-aliquoted, re-frozen
at –80 ° C, and then individual aliquots thawed imme-
diately prior to use. The urinary concentrations of 128
analytes were measured by coupled bead assay (Luminex
using MILLIPLEX® Map Kits (EMC Millipore Corporation),
Eve Technologies Inc.) Further information regarding the
sensitivity and dynamic range of the assays can be found on
the company website (http://www.emdmillipore.com/). For
the majority of assays, the urine samples were run un-
diluted except: KIM-1 and renin (diluted 1/2); albumin,
beta-2-microglobulin, clusterin, cystatin C, and osteopontin
(diluted 1/50); and TIMP-1 and TIMP-2 (diluted 1/5). For
the discovery phase, all analytes were measured in
duplicate for ALN patient samples, with a single sample
on each of two separate plates, and averaged. ANLN and
HC samples were measured in singles and randomly
assigned to one of the two plates with equivalent numbers
for each group per plate. As the duplicates run on separate
plates were very reproducible, samples in the validation
phase were run in singles on a single plate. All results
were normalized to urinary creatinine prior to analysis.
Renal histopathology scoring
ISN-RPS histopathological class [30] and activity and
chronicity scores [31, 32] were determined by an indi-
vidual renal pathologist (CA-C), blinded to the results of
the urine protein determination.
Statistical analyses of discovery data
Normalized protein data were loaded into the R statistical
environment (v3.1.1) for analyses. Data were scaled using
the standard deviation for each variable and hierarchical
clustering performed using divisive analysis (DIANA) with
a Pearson’s correlation as a similarity metric. The Adjusted
Rand Index, available in the mclust package (v4.4), was
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used to corroborate the clustering. Normalized abundance
data were correlated with clinical variables across all
patients using Spearman's correlation, followed by false
discovery rate (FDR) adjustment of the p values to correct
for multiple testing. A Venn diagram was generated using
the VennDiagram package (v1.6.9) to visualize the overlap
of significantly correlated genes among clinical variables
[33]. Data were log2 transformed and linear modeling was
performed with the limma package (v3.20.9) in R to iden-
tify proteins with significant differences in abundance
between groups. An empirical Bayes moderation of the
standard error [34], followed by FDR correction, was
employed [35]. Coefficients (i.e., log2 fold-changes relative
to control samples) that were determined to be signi-
ficantly different from 0 following FDR correction (padj <
0.01) were carried forward. A Venn diagram was gene-
rated (as described above) to visualize overlap of signifi-
cantly altered proteins among clinical variables, with
hypergeometic testing performed to determine if overlap
was greater than expected by chance alone. Finally, results
(magnitude, direction, and significance of change) were
visualized in a dotmap using the lattice (v0.20-29) and
latticeExtra (v0.6-26) packages for R.
A receiver operating characteristic (ROC) analysis was
performed to evaluate the ability of various analytes to
discriminate between active patients with or without
nephritis, or with and without proliferative changes on
renal biopsy. A total of 9 analytes were evaluated using
data from 85 active lupus patients for the analysis of
nephritis and 8 analytes on 60 patients with paired renal
biopsies for analysis of proliferative nephritis. The pROC
package (v1.8) for R (v3.2.1) was used to calculate the
true positive (sensitivity) and false positive (1 – specifi-
city) rates across various analyte level thresholds, along
with the area under the curve (AUC). ROC curves were
created using the lattice (v0.20-33) and latticeExtra
(v0.6-26) packages for R.
To assess the ability of selected analytes alone or in
combination with conventional biomarkers to discrimin-
ate between proliferative and non-proliferative/chronic
nephritis, all possible combinations of conventional
biomarkers (C3, anti-dsDNA, albuminuria) and the top
performing univariate analytes associated with the acti-
vity index (vWF, IP-10, PDGF-BB, IL-16, adiponectin)
were evaluated. Samples were divided into four balanced
folds (such that each fold contained a similar number of
active proliferative (1) and non-proliferative (0) nephritis
patients). For each combination of analytes, a linear
model was fit using disease status (1/0) as the response
to be predicted by the indicated analytes (i.e., response
~ analyte.1 + analyte.2 …). Each model was trained using
data from three of the four folds, with the fourth fold
used for testing. This process was repeated four times
such that each fold was used for testing only once. Mean
sensitivity, specificity, and accuracy were calculated across
the four repetitions.
Statistical analysis of validation data
Statistical significance of differences between groups
(e.g., ALN and ANLN) was determined using the Mann-
Whitney U test with a Bonferroni correction for multiple
comparisons.
Results
A cluster of urinary proteins identifies patients with
active LN
Urinary concentrations of 128 analytes (see Additional
file 1: Table S1) were determined in SLE patients with
ALN or ANLN, and HC, and normalized to urinary creati-
nine. Both SLE groups were comparable with respect to
age, sex, and disease activity, although patients with ALN
were on higher mean doses of prednisone and more
immunosuppressive medications as compared with ANLN
(Table 1). Hierarchical clustering (Fig. 1a) demonstrated
that distinct groups of analytes identified ALN patients
versus both HC and patients with ANLN (Adjusted Rand
Index = 0.138, a measure of agreement between clusters
with 0 indicating no agreement and 1 complete agree-
ment), with no specific protein cluster discriminating
between the latter two groups. These results suggested
that a discrete number of urinary proteins preferentially
identified patients with ALN.
To explore the relationship between individual urinary
analytes and the three clinical states, linear modeling
was performed. No statistically significant difference in
urinary protein expression was seen when comparing all
SLE patients (ALN and ANLN) to HC (Fig. 1b, left
column). In contrast, statistically significant differences
in analyte levels (padj < 0.01) were noted between the two
active SLE populations with 44 proteins preferentially
elevated in patients with ALN (Fig. 1b, right column,
and Table 2). Differences between the two patient popu-
lations were striking, with 13 proteins having >4-fold
(2 log2 fold-change in the table) difference in the mean
urinary concentration between patients with ALN versus
ANLN, five of which (adiponectin, PAI-1, IL-15, PF4, and
TIMP-1) demonstrated >8-fold increase in abundance
(Fig. 2a). The concentration of these analytes in patients
with ANLN was statistically indistinguishable from levels
detected in HC, supporting their candidacy as LN-specific
biomarkers. In further support of the concept that these
biomarkers are specific for active renal disease in SLE,
there was no association between the SLEDAI and urinary
analyte levels in ANLN patients, and any significant asso-
ciations between the SLEDAI and urinary analyte levels in
the total patient cohort (or ALN subset) were lost when
the renal components of the SLEDAI were removed from
the calculation.
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Novel candidate urinary biomarkers outperform currently
proposed LN activity-specific biomarkers
MCP-1, TWEAK, NGAL, and sVCAM have been pro-
posed as potential LN activity-specific biomarkers in
adult and pediatric SLE patients [7–9, 11–23, 25–27].
Our findings confirmed that these urinary analytes are
elevated in the urine of ALN as compared to ANLN
patients (Fig. 2b and Table 2). However, the differences
between the two patient populations were not as marked
as those noted for many of our newly identified urinary
analytes. These results suggest that our newly identified
proteins may have a greater capacity to discriminate ALN
from ANLN. To assess this possibility we contrasted
the receiver operating characteristics (ROC) for the five
analytes with the highest fold-difference between ALN and
ANLN, with previously proposed urinary and serum
(C3, anti-dsDNA) biomarkers, as well as established
markers of renal dysfunction (Table 3; see Additional
file 1: Figure S1). With the exception of sVCAM, the
AUCs were higher and the sensitivities and specificities at
Table 1 Demographic and clinical variables for SLE patients in discovery and validation cohorts
Discovery Validation
Demographic variables SLE
Active LN
(n = 60)
SLE
Active non-LN
(n = 25)
Healthy controls
(n = 24)
SLE
Active LN
(n = 33)
SLE
Active non-LN
(n = 16)
SLE
Remission LN
(n = 30)
Age
Range (years) 18–64 18–61 23–47 18–56 19–67 19–67
Mean ± SD (median) 35.5 ± 12.7 (32) 30.0 ± 11.9 (26) 32.8 ± 6.7 (31) 28.5 ± 9.5 (27) 36.8 ± 15.9 (36) 40.0 ± 13.6 (40.5)
Gender, n (%) female 46 (82.1) 22 (88) 21 (87.5) 28 (84.8) 15 (93.8) 28 (93.3)
Ethnicity, n (%)
Caucasian 29 (48.3) 9 (36) 14 (58.3) 14 (42.4) 6 (37.5) 20 (66.7)
African Canadian 14 (23.3) 7 (28) 1 (4.2) 8 (24.2) 2 (12.5) 4 (13.3)
Asian 9 (15) 5 (20) 3 (12.5) 5 (11.6) 2 (12.5) 2 (6.7)
Othera 8 (13.3) 4 (16) 6 (25) 6 (18.2) 6 (37.5) 4 (13.3)
Clinical featuresb, n (%)
Rash 8 (14.3) 12 (48) N/A 11 (33.3) 3 (18.8) 0
Mucocutaneous 9 (16.1) 9 (36) N/A 0 2 (12.5) 0
Alopecia 4 (7.1) 7 (28) N/A 4 (12.1) 5 (31.2) 1 (3.3)
Arthritis 13 (23.2) 13 (52) N/A 3 (9.1) 9 (56.2) 0
Serositis 8 (14.3) 4 (16) N/A 2 (6.1) 1 (6.2) 0
Myositis 1 (1.8) 0 N/A 0 1 (6.2) 0
Hematological 6 (10.7) 6 (24) N/A 2 (6.1) 3 (18.8) 0
Fever 3 (5.4) 1 (4) N/A 1 (3.0) 2 (12.5) 0
Nephritis (≥1 or more SLEDAI-2 K criteria) 59 (98.3)c 0 N/A 33 (100) 0 1 (3.3)
Vasculitis 3 (5.4) 7 (28) N/A 2 (6.1) 3 (18.8) 0
SLEDAI-2 K, mean ± SD (median) 15.6 ± 7.4 (16) 10.1 ± 4.7 (10) N/A 14.2 ± 5.6 (14) 7.2 ± 2.7 (8) 1.7 ± 1.9 (1)
Creatinine, mean ± SD (median) 118.0 ± 78.8 (87) 64.5 ± 9.6 (62) N/A 91.8 ± 81.1 (69) 69.2 ± 16.0 (70.5) 81.8 ± 25.3 (75.5)
Medicationsb
Prednisone (mg/day), mean ± SD (median) 28.5 ± 20.8 (30) 10.8 ± 30.4 (0) N/A 21.8 ± 18.8 (15) 8.5 ± 13.2 (4) 6.1 ± 6.9 (4)
Anti-malarials, n (%) 31 (55.4) 15 (60) N/A 21 (63.6) 13 (81.2) 24 (80)
Immunosuppressives, n (%) 55 (91.7) 5 (20) N/A 27 (81.8) 10 (62.5) 22 (73.3)
Azathioprine, n (%) 9 (16.1) 3 (12) N/A 11 (33.3) 3 (18.8) 9 (30)
Mycophenolate mofetil, n (%) 15 (26.8) 1 (4) N/A 9 (27.3) 2 (12.5) 10 (33.3)
Methotrexate, n (%) 1 (1.8) 1 (4) N/A 1 (3.0) 5 (31.2) 1 (3.3)
In the validation cohort, eight patients had renal biopsies an average of 10 days from sample accrual
aOther ethnicities include Hispanic, Filipino, mixed, and, for three healthy controls, unknown ethnicity
bClinical variables and treatment at time of recruitment
cOne patient had a renal biopsy performed for 0.45 g/24 h proteinuria
LN lupus nephritis, N/A not applicable, SD standard deviation, SLE systemic lupus erythematosus, SLEDAI-2 K Systemic Lupus Erythematosus Disease
Activity Index-2000
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optimal cut-offs were improved as compared to existing
biomarkers. Furthermore, for many of the analytes, the
AUC and sensitivities approached those seen for albumin-
uria, with several of the analytes demonstrating improved
specificity over this conventional measure.
Notably, within the subset of patients with ALN, there
was a poor correlation between the levels of these ana-
lytes and albuminuria (ρ ranging from 0.14 for TIMP-1
to 0.49 for IL-15), eGFR (ρ ranging from –0.04 for
adiponectin to –0.57 for TIMP-1) or SLEDAI (ρ ranging
from 0.16 for TIMP-1 to 0.38 for adiponectin). Repre-
sentative plots showing the analytes with the strongest
correlation for each of these parameters are shown in
Fig. 2c.
A subset of urinary biomarkers correlates with the
presence of active proliferative renal lesions on
histopathology
As all of the ALN patients in the discovery cohort had a
renal biopsy performed close to the time of their urine
sampling (see Additional file 1; biopsy characteristics
summarized in Additional file 1: Table S2), a Spearman
correlation analysis followed by correction for multiple
testing was performed to further delineate the relationship
between urinary analytes and renal disease activity. Ten
proteins (adiponectin, PAI-1, IL-16, wVF, IP-10, TIMP-1,
eotaxin, sgp130, HGF, and PDGF-BB) were found to
significantly correlate with renal biopsy activity score (q <
0.01; see Additional file 1: Table S3), with no analytes
correlating with chronicity scores. Of the individual com-
ponents of the activity index, only glomerular hyaline
thrombi/wire loops and interstitial monocytes were not
independently associated with these urinary biomarkers,
with the strongest association being with the cellular
crescents sub-score (ρ = 0.39 to 0.63) for the majority of
the biomarkers.
Given that the activity score is driven primarily by
histopathological features associated with proliferative
lesions [31, 32], we examined whether any of these acti-
vity index-associated proteins discriminated between
active proliferative (ISN/RPS III (A or A/C), IV (A or A/
C)) and other renal lesions including non-proliferative
(ISN/RPS I, II, V) or chronic lesions (ISN/RPS III (C), IV
(C), V (C) or VI). As shown in Fig. 3a, eight of these pro-
teins were found to significantly discriminate between
proliferative and non-proliferative or chronic lesions
(see Additional file 1; ROC analysis shown in Additional
file 1: Table S4), and similar findings were observed when
Fig. 1 Urinary protein differences between patient groups. a Urinary protein levels for 85 systemic lupus erythematosus (SLE) patients
(60 active LN, 25 active non-LN) and 24 controls in the discovery cohort. Shown are hierarchical clustering results for the 128 analytes
tested as measured by Luminex. Signal intensities were adjusted using SD scaling, with green indicating overexpression. Hierarchical
clustering was performed on the samples (rows) and proteins (columns) using divisive analysis. b Log2 fold-change of normalized protein
abundance for comparisons between SLE patients and healthy controls (left column) and between active SLE patients with and without
LN (right column). The size of the circles indicates the fold-change for the comparison, with orange circles indicating overexpression and
blue circles indicating underexpression in all SLE patients (left column) or patients with LN (right column). The background in each row/
column indicates the statistical significance of the comparison as determined by multivariate linear modeling followed by FDR correction
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just the subset of class III/IV patients with chronic lesions
was examined. For four of these analytes, the increases
detected in ALN were driven solely by patients with active
proliferative lesions, indicating that some urinary bio-
markers may be specific for proliferative lesions. In
contrast, urinary elevations of albumin, IL-15, and PF4
did not differentiate between proliferative and non-
proliferative/chronic lesions on biopsy, but appeared to
effectively discriminate patients with non-proliferative/
chronic lesions from patients without LN (Fig. 3b).
Notably, none of the urinary analytes discriminated
between class II or V and chronic renal lesions, nor were
there urinary analytes that could discriminate between
class III and IV LN. There were no significant differences
in the levels of the urinary analytes between class III/IV
patients with or without class V changes. Although there
were trends to higher levels of the activity-correlated uri-
nary proteins in class IV as compared to class III nephritis
and in class IV-G as compared to class IV-S nephritis,
these did not achieve statistical significance when cor-
rected for multiple comparisons. There was no association
between corticosteroid dose at the time of urine sampling
and the levels of any of the urinary analytes.
To investigate whether measurement of urinary ana-
lytes associated with the activity index results in an
improved ability to discriminate between active prolife-
rative and non-proliferative or chronic nephritis over
conventional biomarkers, such as anti-dsDNA, C3, and
albuminuria, we performed a multivariate analysis asses-
sing all combinations of these conventional biomarkers
together with the top five performing urinary analytes
from the univariate analysis. The most accurate combi-
nation of conventional biomarkers was C3 and dsDNA
(accuracy of 0.7675, sensitivity 0.875, specificity 0.5925).
A number of different combinations of two to four
urinary analytes together with anti-dsDNA had improved
specificities and accuracies over this combination (see
Additional file 1: Table S5), with the top performing com-
bination being anti-dsDNA+ vWF + IP-10 + PDBG-BB +
adiponectin (accuracy 0.8325, sensitivity 0.87, specificity
0.7675). These findings support the potential clinical utility
Table 2 Results of statistical analysis of discovery and validation
cohorts
Discovery cohort Validation cohort
Urinary
analyte
Log2
fold-difference
ALN vs ANLN
padj* padj*
ALN vs ANLN
padj*
ALN vs RLN
Adiponectin 4 ≤0.0001 ≤0.0044 ≤0.0018
PAI-1 3.77 ≤0.0001 ≤0.0044 ≤0.0018
IL-15 3.32 ≤0.0001 ≤0.0044 ≤0.0018
PF4 (CXCL4) 3.04 ≤0.0001 ≤0.0044 ≤0.0018
TIMP-1 3.01 ≤0.0001 ≤0.0044 ≤0.0018
IL.16 2.97 ≤0.0001 0.62 N/A
Albumin 2.95 ≤0.0001 0.022 1
MPO 2.62 ≤0.0001 0.81 N/A
vWF 2.5 ≤0.0001 ≤0.0044 ≤0.0018
sVCAM-1 2.49 ≤0.0001 ≤0.0044 ≤0.0018
IL-6 2.46 ≤0.0001 0.0088 ≤0.0018
BCA-1 2.22 ≤0.0001 0.54 N/A
SAP 2.19 0.001 0.33 N/A
KIM-1 1.95 ≤0.0001 0.044 0.013
GRO 1.93 ≤0.0001 ≤0.0044 0.0054
HCC-1 (CCL14a) 1.91 ≤0.0001 ND N/A
SCF 1.89 ≤0.0001 1 N/A
MMP-9 1.89 0.007 1 N/A
Cystatin C 1.87 ≤0.0001 0.044 0.0072
sFas 1.76 ≤0.0001 0.18 N/A
PDGF-BB 1.7 0.005 0.80 N/A
GCP-2 (CXCL6) 1.69 ≤0.0001 ≤0.0044 ≤0.0018
IL-8 1.66 0.002 0.0088 0.26
Clusterin 1.58 ≤0.0001 ≤0.0044 ≤0.0018
Eotaxin 1.58 0.002 1 N/A
MMP-7 1.56 0.002 0.022 ≤0.0018
MMP-2 1.56 ≤0.0001 1 N/A
TARC 1.48 ≤0.0001 1 N/A
HGF 1.47 ≤0.0001 0.44 N/A
NAP-2 (CXCL7) 1.47 0.001 1 N/A
Perforin 1.37 ≤0.0001 1 N/A
MCP-1 1.34 ≤0.0001 ≤0.0044 ≤0.0018
IFNγ 1.29 0.005 1 N/A
GM-CSF 1.24 0.007 0.0088 0.013
Eotaxin-2 1.22 ≤0.0001 1 N/A
TWEAK 1.16 0.001 0.54 N/A
I-TAC (CXCL11) 1.13 0.007 0.079 N/A
sIL-1RI 1.12 0.003 1 N/A
sgp130 1.07 ≤0.0001 1 N/A
Table 2 Results of statistical analysis of discovery and validation
cohorts (Continued)
sTNFRI 1.06 0.004 1 N/A
MCP-3 1.02 0.006 1 N/A
TIMP-2 1.01 0.002 1 N/A
NGAL 0.95 0.01 ND N/A
VEGF 0.72 0.007 1 N/A
X6CKine –3.15 ≤0.0001 1 N/A
*p values have been adjusted for multiple testing to reduce the false
discovery rate
N/A not applicable, ND not determined
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of measurement of these activity-specific biomarkers in the
diagnosis of active proliferative nephritis.
Validation of potential urinary biomarkers in a secondary
cohort and normalization in renal remission
To validate the findings in the discovery cohort, we mea-
sured the levels of the significantly increased urinary ana-
lytes from this cohort in a second independent cohort of
33 ALN and 16 ANLN SLE patients (see demographics in
Table 1). In this smaller cohort, 18 of the original analytes
identified replicated, including all five of the urinary
analytes that previously demonstrated >3 log2 fold-increase
in LN (Table 2 and Fig. 4).
A key requisite of an activity-specific LN biomarker is
normalization during renal remission. Therefore the levels
of the replicated urinary LN biomarkers in the ALN
patients were contrasted with those in 30 patients with
previous LN that were in remission. Of the 18 replicated
urinary analytes, all but two (albumin and IL-8) norma-
lized in patients in remission (Table 2 and Fig. 4). These
findings support the potential clinical utility of these ana-
lytes as biomarkers of active renal involvement in SLE.
Discussion
In this study we used an unbiased proteomics-based
approach to compare the levels of 128 proteins in the
urine of active SLE patients with and without LN. We
show that many urinary proteins are elevated in patients
with ALN, with approximately one-third of the analytes
tested being at least 2-fold increased in the urine of
patients with ALN as compared to ANLN. These proteins
represent a broad array of molecules, many of which have
been implicated in the pathogenesis of nephritis through
diverse mechanisms including: cyto/chemokines and their
Fig. 2 Comparison of the most highly discriminative urinary analytes to several previously proposed biomarkers. Scatter plots showing the normalized
concentration of selected urinary proteins in healthy controls (HC; n = 24, open circles) and SLE patients with active non-LN (ANLN; n = 25, closed circles)
or active LN (ALN; n = 60, closed triangles). Urinary concentrations were corrected for creatinine to normalize for osmolality. Units for all graphs are
pg/μmol, except PF4 and TWEAK which are in ng/μmol. a Urinary analytes that demonstrated >3 log2 fold-difference between ANLN and ALN.
b Previously proposed urinary biomarkers. For all graphs each symbol represents the determination from a single individual, with the mean value
for each group indicated by a horizontal line. Fold-differences and statistical comparisons for the analytes are shown in Table 2. c Correlation between
the urinary analytes that demonstrated >3 log2 fold-difference between ANLN and ALN and that showed the strongest association with albuminuria,
estimated glomerular filtration rate (GFR), or Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI). Lines indicate linear regression
curves. Spearman’s correlation coefficients are shown
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receptors (e.g., IL-15 and PF4), metalloproteinases and
their regulators (e.g., TIMP-1 and MMP-9), growth factors
(e.g., GM-CSF), markers of endothelial injury/repair
(e.g., adiponectin, PAI-1, and vWF), and markers of kidney
damage (e.g., KIM-1 and cystatin C).
Although elevated levels of multiple proteins were
seen in the urine of patients with ALN, these elevations
did not appear to result solely from the decreased filte-
ring capacity of the kidney in LN. For those urinary
analytes that demonstrated >4-fold increase in the urine
of ALN patients, there was no or only a weak correlation
with albuminuria (Fig. 2c, and data not shown). Further-
more, consistent with previously published reports [7–13],
we have previously observed a poor correlation between
serum and urine levels of MCP-1, adiponectin, and
sVCAM-1 (unpublished observations). These findings
suggest that the elevated levels of urinary proteins in LN
reflect increased elaboration within the kidney as a conse-
quence of active inflammation. In support of this concept,
increased kidney expression of many of the proteins iden-
tified in the current study has been described in various
nephritis models [10, 13, 36–39].
A highlight of our study was the identification of a
number of biomarkers for ALN with markedly elevated
urinary levels as compared to ANLN and remission LN
(>4–8-fold). Of the nine urinary proteins in this group
that replicated in the validation cohort, four have been
previously reported to be elevated in ALN. These include
adiponectin [10], albumin [40], sVCAM-1 [13, 25–27],
and IL-6 [41, 42]. The remaining five, including PAI-1,
IL-15, PF4, TIMP-1, and vWF, represent novel potential
urinary biomarkers that have not previously been described
in LN. Notably, a number of these biomarkers appeared
to outperform previously proposed biomarkers such as
NGAL, MCP-1, and TWEAK, with improved sensitivities
and specificities at optimal cut-offs. These differences
do not appear to reflect differences in the ability of the
Luminex system to detect these previously reported
biomarkers, because the fold-increases and sensitivity and
specificity at optimal cut-offs were very similar in our study
to those observed in previous studies [7, 11, 15, 18, 23].
While several of the biomarkers that demonstrated
the greatest fold-differences between ALN and ANLN
demonstrated very high sensitivities (up to 93 %) and
specificities (up to 96 %), no one biomarker appeared
to be sufficient to diagnose ALN with 100 % accuracy, and
it is likely that a panel of biomarkers may more optimally
discriminate LN from other disease states. Based upon
our ROC results, it is probable that a panel consisting of a
combination of a subset of the five analytes demonstrating
>8-fold difference between ALN and ANLN would offer
the best discriminative ability; however, this will require
testing in an independent unselected cohort of SLE
patients with both active and inactive disease.
Previous work has shown that renal biopsies demon-
strating diffuse proliferative (class IV) LN and increased
glomerular activity indices are associated with a poorer
long-term prognosis [31, 32, 43, 44], an increased likeli-
hood of re-flare [45], and increased chronicity scores on
subsequent renal biopsies with glomerulosclerosis and
consequent renal functional deterioration [46]. Given
the invasive nature of renal biopsies, there has been
considerable interest in the identification of urinary bio-
markers that accurately reflect renal disease activity scores
and/or proliferative nephritis. In this study, we identified
10 urinary analytes that showed a strong correlation with
the renal biopsy activity score. Although several urinary
proteins, including sVCAM [47], NGAL [8, 48], MCP-1
[48, 49], adiponectin [48], KIM-1 [48], and TWEAK [24],
have been previously reported to correlate with the acti-
vity index on renal biopsy, with the exception of adiponec-
tin none of these analytes were replicated in our study.
Thus, we have identified nine novel proteins that are more
closely associated with the activity index on renal biopsy
than all previously reported associated proteins except
adiponectin. Notably, addition of various combinations of
the five top performing analytes associated with the acti-
vity index to conventional biomarkers of renal disease
activity (C3, anti-dsDNA, and albuminuria) resulted in an
improved ability to discriminate between active prolifera-
tive and non-proliferative or chronic nephritis, supporting
their potential clinical utility for the diagnosis of active
proliferative nephritis.
Recently a composite urinary biomarker activity index
was reported based upon the urinary levels of six pro-
teins, including adiponectin, NGAL, MCP-1, KIM-1,
ceruloplasmin, and hemopexin, that can differentiate
pediatric LN patients with high activity indices on renal
Table 3 Results of the ROC analysis for diagnosis of ALN
Analyte Sensitivity Specificity AUC Best cut-off
Adiponectin 0.77 0.92 0.88 1.86 × 103
PAI-1 0.82 0.92 0.90 4.47 × 10–1
IL-15 0.70 0.96 0.84 3.05 × 10–1
PF4 0.93 0.76 0.90 2.44 × 10–3
TIMP-1 0.90 0.84 0.91 1.26 × 102
sVCAM 0.83 0.76 0.81 5.29 × 102
MCP-1 0.75 0.84 0.81 1.25 × 102
TWEAK 0.47 0.96 0.73 2.73 × 10–2
NGAL 0.85 0.48 0.69 3.35 × 103
Albumin 0.95 0.84 0.93 4.90 × 106
Creatinine 0.58 0.96 0.76 8.05 × 101
C3 0.57 0.72 0.57 7.60 × 10–1
anti-dsDNA 0.30 0.80 0.48 1.00 × 102
ALN active lupus with lupus nephritis, AUC area under the curve, ROC receiver
operating characteristic
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Fig. 4 Normalization of urinary protein levels in LN patients in remission. Scatter plots showing the normalized concentration of selected urinary
proteins in SLE patients from the validation cohort with active non-LN (ANLN; n = 16, closed circles), active LN (ALN; n = 33, closed triangles) or LN in
remission (RLN; n = 30, open triangles). Units for all graphs are pg/μmol, except for PF4 which is in ng/μmol. Each symbol represents the determination
from a single individual, with the mean value for each group indicated by a horizontal line. Statistical comparisons for the analytes are shown
in Table 2
Fig. 3 Urinary proteins that discriminate between proliferative and non-proliferative/chronic lesions on renal biopsy. Scatter plots showing the
normalized concentration of selected urinary proteins in SLE patients with proliferative LN (Prol; Class III and IV (A) or (A/C), n = 38, closed triangles)
and non-proliferative or chronic lesions (NPC; Class I, II, V, or VI, and Class III or IV (C), n = 22, open triangles) on renal biopsy as compared to active
SLE patients without LN (NLN; n = 25, closed circles). Units for all analytes are pg/μmol, except vWF and PF4 which are in ng/μmol. a Plots for the
eight urinary proteins that discriminated between proliferative and NPC lesions on renal biopsy. In the two columns on the right of each plot the
NPC results have been subdivided into chronic class III/IV (III/IV(C)) and other non-proliferative/chronic lesions (NP). b Plots for three representative
urinary proteins that did not discriminate between proliferative and non-proliferative or chronic lesions on renal biopsy, demonstrating their ability
to discriminate between non-proliferative/chronic lesions and active non-LN. For all graphs, each symbol represents the determination from a single
individual, with the mean value for each group indicated by a horizontal line. Significance levels were determined by Mann-Whitney non-parametric
testing and have been corrected for multiple testing. Only the differences between proliferative and non-proliferative/chronic lesions, and
non-proliferative/chronic lesions and active non-LN for each analyte are shown. In graphs in panel (a), significant differences between active
proliferative and chronic class III/IV lesions are also indicated, and represent uncorrected p values. *p < 0.05, **p <0.005, NS not significant
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biopsy from those with low or moderate activity indices
with >92 % accuracy [48]. Our findings raise the possibility
that further improvements in this accuracy might be
possible through the use of alternate biomarkers that are
more closely associated with renal disease activity, a possi-
bility that can be addressed in further studies.
Given the large number of urinary analytes examined
in our discovery cohort, it was important to replicate
these findings. Although only 18 of the biomarkers
examined were replicated, it is likely that this results
from several differences between our discovery and vali-
dation cohorts. Firstly, our validation cohort was signifi-
cantly smaller in size (approximately half the size of our
discovery cohort) which may have restricted our ability to
detect less robust biomarkers. Additionally, the majority
of patients in our validation cohort with ALN were
re-flaring, usually after several years of treatment,
whereas the majority of the patients in the discovery
cohort had new-onset LN. As previous work suggests
that repeat flares are associated with an increased like-
lihood of chronic rather than active changes [50], this
might have affected our ability to replicate urinary ana-
lytes that are associated predominantly with active proli-
ferative lesions, such as IL-16, PDGF-BB, sgp130, and
eotaxin. Finally, there may have been significant diffe-
rences between the cohorts in the distribution of renal
biopsy classes (e.g., more class V in the validation cohort),
which may also have affected our ability to replicate these
differences. If the inability to validate these activity-
associated analytes is related to these cohort differences,
then these biomarkers may still be clinically useful as
biomarkers that are specific for active class III/IV LN.
The majority of the validated urinary analytes were
found to normalize in patients who had achieved renal
remissions. These findings suggest that measurement of
these urinary proteins will have clinical utility for moni-
toring responses to therapy and prediction of flare, as
has been shown for some of the previously published
urinary biomarkers, such as NGAL [12, 18–21] and
TWEAK [23]. Longitudinal studies are ongoing to define
which combination of the previously published bio-
markers and novel biomarkers identified in this study
best reflects changes in LN activity and response to the-
rapy, with the goal of defining an optimal biomarker
panel for the monitoring of LN.
Conclusions
Using a proteomics approach, novel urinary biomarkers
were identified and validated that discriminate between
active SLE patients with and without nephritis, and
normalize in patients in remission. Several of these novel
urinary proteins offer improved discriminative ability
over many previously identified urinary biomarkers. A
subset of these urinary proteins effectively discriminated
between active proliferative and non-proliferative/chronic
lesions in paired renal biopsies, suggesting that they may
have clinical utility in the identification of patients that
may require more aggressive therapy.
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